Results 211 to 220 of about 1,105,809 (304)

Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. [PDF]

Front Med (Lausanne)
Weaver MS, Flynn JS, Li J, Armstrong GM, Harrison LW, Mandrell BN, Wooten ZT, Johnson LM, Nichols KE, Howard Sharp KM.   +9 more
europepmc   +1 more source

Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab

International Forum of Allergy &Rhinology, EarlyView.
Emeline Delaunay, Stephane Esnault, Arnaud Dendooven, Jacques Trauet, Céline Desvant, Guillaume Lefèvre, Geoffrey Mortuaire   +6 more
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

The multidimensional roles and mechanisms of exercise intervention in pediatric oncology. [PDF]

Front Immunol
Dai S, Yang Z, Wu Y, Wu M, Ma M, Zhang X, Tang H, Ye X, Du M.   +8 more
europepmc   +1 more source

Serous versus Mucinous Submucosal Gland Composition in Chronic Rhinitis With Clear Thin Rhinorrhea

International Forum of Allergy &Rhinology, EarlyView.
Emmanuel D. Meram, Geoffroy Laumet, Wamidh Alkhoory, Jun Jin, John R. Craig   +4 more
wiley   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

Communicating cancer diagnoses with children in Japan: A qualitative study of healthcare professionals' beliefs and approaches in pediatric oncology. [PDF]

Palliat Care Soc Pract
Yamaji N, Yotani N, Ikeda M, Hasegawa T.
europepmc   +1 more source

The impact of medication shortages on paediatric care: A retrospective impact analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Medication shortages are a growing global concern, with potentially greater consequences in paediatric patients because of the limited availability of safe, evidence‐based and appropriately formulated medication. This study aimed to evaluate the impact of medication shortages on paediatric patients by assessing the suitability and safety of ...
Maaike Johanna Rutten ‐ van Kranenburg, Laurens Christiaan van Rijn, Elisabeth Johanna Ruijgrok, Sinno Henricus Paulus Simons, Brigitta Carolina Maria Witjes, Jan‐Dietert Christoffer Brugma, Robert Bernard Flint   +6 more
wiley   +1 more source

Transition from drug lag to drug loss in pediatric oncology: a comprehensive evaluation of the Japan-U.S. approval gap. [PDF]

Front Pharmacol
Yamada K, Sato H, Hirakawa A.
europepmc   +1 more source